Greenwich LifeSciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company that develops novel peptide immunotherapies targeting HER2/neu-expressing cancers, primarily focused on preventing breast cancer recurrences in high-risk patients who have completed standard trastuzumab-based therapy. The company's lead product candidate is GLSI-100, a proprietary combination of GP2--a nine-amino acid transmembrane peptide derived from the HER2/neu protein--and GM-CSF adjuvant; GP2 is designed to stimulate immune responses against cancer cells expressing HER2/neu at low (1+), intermediate (2+), or high (3+) levels, which occurs in approximately 75% of breast cancers and other HER2-positive tumors. GLSI-100 is currently advancing through the global Flamingo-01 Phase III clinical trial, a randomized, double-blinded study enrolling up to 750 patients across up to 150 sites to evaluate its safety and efficacy in reducing recurrence rates, building on Phase IIb data showing an 80% or greater reduction in metastatic recurrences over five years with a favorable safety profile. Founded in 2006 and headquartered in Stafford, Texas, a suburb of Houston, Greenwich LifeSciences operates in the United States and Europe, with clinical trial sites spanning networks including US Oncology, GEICAM (Spain), Unicancer (France), GBG (Germany), GIM (Italy), and Polish groups, as well as leading institutions such as MD Anderson Cancer Center, Harvard, and Johns Hopkins. The company maintains manufacturing readiness with up to 200,000 commercial doses of GP2 available ahead of potential BLA filing and explores pipeline expansion opportunities into HER2 1-2+ patients with Herceptin, other HLA types, CD4/CD8 peptide combinations, checkpoint inhibitors, and additional HER2/neu cancers. Recent developments include the expansion of the Flamingo-01 trial into new European countries such as Austria, Belgium, Portugal, Ireland, Spain, France, Germany, Italy, Poland, and Romania following regulatory approvals; strategic partnerships with clinical networks like GBG in Germany and Unicancer in France; FDA Fast Track designation for GLSI-100; a planned internal build-out of key clinical functions to reduce trial costs; and a $2.5 million private placement in June 2024 led by CEO Snehal Patel to support clinical development and working capital. As of December 2025, the trial has screened over 1,000 patients globally, with an interim analysis planned based on prior Phase IIb efficacy signals outperforming approved HER2 therapies like Herceptin and Kadcyla. Oversight is provided by a distinguished Steering Committee of global oncology key opinion leaders, including experts from Baylor, Northwestern, and University of California San Francisco.
Company News
20 stocks likely to lose money even if the bull market continues
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
Greenwich LifeSciences The Overlooked Need
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026